Verrica Pharmaceuticals to Present YCANTH® and VP-315 Data at Two Upcoming Dermatology Conferences
Post-hoc analysis shows YCANTH® drove high rates of complete clearance in molluscum contagiosum patients regardless of disease duration —WEST CHESTER, Pa., Sept. 10, 2026 (GLOBE NEWSWIRE) -- Verrica Pharmaceuticals Inc. (“Verrica” or the “Company”) NASDAQ:VRCA, a therapeutics company developing a…
This is a real-time flash headline. A verified provider body is not available, so SquawkNews does not present it as a full article.